Chronic administration of H2-antagonists does not alter gastric secretory responses to histamine, or the antisecretory activity of sufotidine

Aliment Pharmacol Ther. 1990:4 Suppl 1:7-13.

Abstract

Gastric secretory responses to histamine were investigated in anaesthetized dogs following treatment with oral ranitidine at 5 mg/kg twice daily for 358 weeks, and in isolated gastric mucosae from mice receiving sufotidine 240-280 mg.kg/day for 15 months. In neither study were there any significant differences between the acid secretory dose-response curves to histamine in control and test animals. The antisecretory activity of oral sufotidine (1 mg/kg) against histamine-induced acid secretion in the Heidenhain pouch dog was unaltered by twice daily dosing with sufotidine for 14 days. These studies on the effects of H2-antagonists on histamine-stimulated acid secretion found no evidence for development of direct tolerance at the parietal H2-receptor level.

MeSH terms

  • Animals
  • Dogs
  • Dose-Response Relationship, Drug
  • Gastric Acid / metabolism*
  • Gastric Mucosa / drug effects
  • Gastric Mucosa / metabolism
  • Histamine / pharmacology*
  • Histamine H2 Antagonists / pharmacology*
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Piperidines / pharmacology*
  • Triazoles / pharmacology*

Substances

  • Histamine H2 Antagonists
  • Piperidines
  • Triazoles
  • sufotidine
  • Histamine